Table 2.
Number of litters with sex-balanced single scores by treatments, endpoint, and rater
| Prenatal treatment | Postnatal challenge | GWS, n | Rater 1 | Rater 2 | ||
|---|---|---|---|---|---|---|
| Ethovision® XT, n | Exclusions, n | Ethovision® XT, n | Exclusions, n | |||
| Saline | 7 | 4 | 3 | 4 | 3 | |
| Vehicle | Ntx1 | 5 | 3 | 2 | 3 | 2 |
| Ntx10 | 4 | 4 | 0 | 4 | 0 | |
| Saline | 3 | 3 | 0 | 3 | 0 | |
| Morphine | Ntx1 | 3 | 2 | 1 | 2 | 1 |
| Ntx10 | 3 | 2 | 1 | 3 | 0 | |
| NorBUP, 0.3 mg/kg/day | Saline | 4 | 4 | 0 | 4 | 0 |
| Ntx1 | 4 | 4 | 0 | 4 | 0 | |
| Ntx10 | 2 | 2 | 0 | 2 | 0 | |
| NorBUP, 1.0 mg/kg/day | Saline | 6 | 5 | 1 | 6 | 0 |
| Ntx1 | 5 | 4 | 1 | 5 | 0 | |
| Ntx10 | 6 | 5 | 1 | 6 | 0 | |
| NorBUP, 3.0 mg/kg/day | Saline | 4 | 3 | 1 | 3 | 1 |
| Ntx1 | 4 | 1 | 3 | 2 | 2 | |
| Ntx10 | 5 | 1 | 4 | 1 | 4 | |
Within each litter, scores from all same-sex littermates were averaged to provide a score for each sex. Male and female scores from each litter (where available) were then averaged to provide the litter’s sex-balanced single score for global withdrawal (GWS) and for the Ethovision® XT endpoints. For purposes of comparing results of the Ethovision® XT analysis with the previous results (Figure 6), the table displays the number of successful analyses per treatment group. Ntx1, naltrexone 1 mg/kg; Ntx10, naltrexone 10 mg/kg